V
Variant Bio
Variant Bio - People-Driven Therapeutics
About Variant Bio
Variant Bio is a biotechnology startup that operates in the healthcare sector, specifically in the field of drug discovery and development. The company's unique approach involves studying the genes of individuals with exceptional health-related traits to gain insights into disease resistance and basis. This information is then used to develop therapies aimed at improving global health.
The company's target market includes healthcare providers and patients worldwide, with a focus on those suffering from diseases that can be addressed through genetic therapies. Variant Bio's business model is based on the development and commercialization of these therapies. The company generates revenue by selling these therapies to healthcare providers or directly to patients.
The team at Variant Bio comprises experts in various fields, including genetics, drug discovery and development, molecular biology, anthropology, and ethics. The company prides itself on its ethical approach to human genomics research, respecting the privacy, beliefs, cultures, and data of the populations they work with. They also have unique benefit-sharing programs to recognize the contributions of partner communities.
In summary, Variant Bio is a biotech startup that uses human genetics research to develop therapies aimed at improving global health. The company operates in the healthcare sector and generates revenue through the sale of these therapies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Seattle, United States
- Employees
- 37
- Open positions
- None listed
- Dealroom signal
- 64.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Nov 2021 | $105M | $420M | Cercano Management · SoftBank · SoftBank Vision Fund · General Catalyst | — |
| SERIES AOther financing | Oct 2019 | $25M | $99M | Casdin Capital · Alexandria Venture Investments · Sahsen Ventures · Alta Partners | — |
Growth signals
Latest recorded traffic for Variant Bio is 5.2K monthly website visits, up 79.3% over the last three months. Variant Bio's team declined 17.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Lux Capital
Casdin Capital
Alexandria Venture Investments
Sahsen Ventures
Alta Partners
SoftBank Vision Fund
Cercano Management
SoftBank
General Catalyst
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Variant Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Variant Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.